– USA, CA – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced Helmy Eltoukhy, CEO, and AmirAli Talasaz, President, now serving as co-CEOs and on the Board of Directors with Helmy Eltoukhy as Chairman.
In addition, Meghan Joyce, COO, and EVP of Platform at Oscar Health will join the Board as an Independent Director.
Following the recent successful launch of new oncology products and the planned launch of a blood-based screening LDT in 2022, the Company has implemented a new leadership structure to support two focused areas within Guardant Health, Oncology, and Screening, to be separately led by Eltoukhy and Talasaz, respectively. Furthermore, this structure will allow for scalability to address new areas across healthcare.
“Our mission at Guardant has always been to ensure patients have access to innovative oncology products. With the recent launches of Guardant Reveal, TissueNext, and Response, that vision is clearer than ever, and we are still just scratching the surface of the need ahead,” said Eltoukhy. “We look forward to continuing to expand our product portfolio and improve patient outcomes as we conquer cancer with data across the continuum of care.”
“Early cancer screening has the potential to significantly transform patient outcomes. As we gain confidence in our screening platform and plan to launch an LDT in the near term, it is clear that this opportunity requires a dedicated and focused effort,” said Talasaz. “We believe that Guardant will be a leader in blood-based screening, starting with CRC and expanding to other cancer types. This enhanced focus on execution will enable us to rapidly build the operational and commercial infrastructure required in this emerging business opportunity. I would also like to welcome Meghan to our Board of Directors. Her expertise in scaling high-growth organizations will be invaluable to our next phase of growth.”
About Meghan Joyce
Meghan Joyce is the COO and EVP of Platform at Oscar Health, a high-growth health tech, and health insurance company, where she leads operations, technology, clinical, marketing, and new business lines. Before joining Oscar Health, Joyce held several leadership roles at Uber Technologies, most recently as Regional General Manager of the United States and Canada. Meghan has previously served as a Senior Policy Advisor at the United States Department of the Treasury, an investor at Bain Capital, and a consultant at Bain & Company. Joyce currently serves as a member of the Board of Directors of The Boston Beer Company, where she sits on the Audit Committee and chairs the Nominating and Governance Committee.
“I am delighted to be joining Guardant’s Board of Directors at a momentous time as the company sets its sights on not only providing solutions for patients with advanced and early-stage cancer but early cancer detection as well,” said Joyce. “Guardant is continuing to develop a portfolio of breakthrough products across all stages of the disease, and I look forward to applying my experience to help Guardant ensure these innovations are not only available but readily accessible for all patients.”
She holds a master’s degree from Harvard Business School and a bachelor’s degree from Harvard College.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets, and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes, and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360, Guardant360 CDx, Guardant360 TissueNext, Guardant360 Response, and GuardantOMNI tests for advanced-stage cancer patients, and Guardant Reveal for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.
For more information: https://guardanthealth.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.